Breaking Finance News

ValuEngine upgraded Mirati Therapeutics, Inc. (NASDAQ:MRTX) to Sell in a report released today.

ValuEngine has upgraded Mirati Therapeutics, Inc. (NASDAQ:MRTX) to Sell in a report released on 7/6/2017.

Yesterday Mirati Therapeutics, Inc. (NASDAQ:MRTX) traded 0.53% higher at $3.30. The company’s 50-day moving average is $4.32 and its 200-day moving average is $4.52. The last closing price is down 5.58% from the 200-day moving average, compared to the S&P 500 which has increased 0.05% over the same time. 111,642 shares of the stock were exchanged, down from an average trading volume of 215,775

See Chart Below

Mirati Therapeutics, Inc. (NASDAQ:MRTX)

Mirati Therapeutics, Inc. has a 52 week low of $2.70 and a 52 week high of $7.22 The company’s market cap is currently $0.

In addition to ValuEngine reporting its target price, a total of 7 brokers have issued a report on the stock. The consensus target price is $30.43 with 4 brokers rating the stock a strong buy, 2 brokers rating the stock a buy, 1 broker rating the stock a hold, 0 brokers rating the stock a underperform, and finally 0 brokers rating the stock a sell.

General Information About Mirati Therapeutics, Inc. (NASDAQ:MRTX)

Mirati Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of oncology products. The companyÂ’s clinical stage product candidates include glesatinib, an orally-bioavailable, potent, small molecule kinase inhibitor that is in Phase II clinical trials for the treatment of non-small cell lung cancer (NSCLC) patients with genetic alterations of MET; and in Phase Ib clinical trials in patients with genetic alterations of MET and Axl in NSCLC and other solid tumors. Its clinical stage product candidates also comprise sitravatinib, an orally-bioavailable, potent, small molecule spectrum-selective kinase inhibitor, which is in Phase II clinical trials for the treatment of solid tumors, such as NSCLC and metastatic Renal Cell Carcinoma, as well as in Phase Ib clinical trials to treat NSCLC patients with RET, CHR4q12, CBL, and AXL genetic alterations; and mocetinostat, an orally administered spectrum-selective Class 1 histone deacetylase inhibitor, which is in Phase Ib/II clinical trials in combination with durvalumab for the treatment of patients with NSCLC. The company has a collaboration agreement with Foundation Medicine, Inc. and Guardant Health, Inc. to explore development of their platforms as companion diagnostics for glesatinib. Mirati Therapeutics, Inc. is headquartered in San Diego, California.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.